Table 1.

Summary of clinical outcomes of HBOT on brain function and other markers in neurodegenerative diseases

Disease	Authors	HBOT	Findings
Mild traumatic brain injury	Boussi-gross et al., 2013	40 sessions at 1.5 ATA, 5 days/week, 60 min/day	Increased brain activity (SPECT, cognition, and quality of life)
Stroke	Boussi-gross et al., 2015	40–60 sessions at 2 ATA, 5 days/week, 90 min/day	Reduction in memory impairments
Alzheimer’s disease	Harch and Fogarty 2018	40 sessions at 1.15 ATA, 5 days/week, 50 min/day	Increase in energy, brain metabolism and cognition
Alzheimer’s disease	Chen et al., 2020	20 sessions at 1.18 ATA, 7 days/week, 40 min/day	Improved cognitive function (Montreal cognitive assessment, mini-mental state examination, and activities of daily living scale)
Parkinson’s disease	Xu et al., 2018	30 days at 2 ATA, 2 sessions of 40 min/day separated by 10-min interval	Improved non-motor symptoms of severe depression and anxiety
Amyotrophic lateral sclerosis	Steele et al., 2004	20 sessions at 2 ATA, 5 days/week, 60 min/day	Decreased fatigue and increased muscle strength